Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544616 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
A Phase 2 study of Preclinical Alzheimer's Disease, sponsored by Janssen Pharmaceutica N.V., Belgium.
- Active
- Registry status
- Phase 2
- Development phase
- 498
- Enrollment target
- 20
- Study locations
NCT06544616 is a Phase 2 study of Preclinical Alzheimer's Disease that is active but no longer recruiting, run by Janssen Pharmaceutica N.V., Belgium. The registered enrollment target is 498 participants, below the 813-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06544616, a Phase 2 study of Preclinical Alzheimer's Disease, is active but no longer recruiting, sponsored by Janssen Pharmaceutica N.V., Belgium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 498 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-64042056
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- Excel Medical Clinical Trials, LLC - Boca Raton
- K2 Medical Research Winter Garden - Clermont
- Clinical NeuroScience Solutions Inc - Jacksonville
- K2 Medical Research - Lady Lake
- K2 Medical Research - Maitland
- Merritt Island Medical Research, LLC - Merritt Island
- Headlands Research Orlando - Orlando
- Alzheimers Research and Treatment Center - Stuart
- K2 Medical Research - Tampa
- Charter Research - The Villages
- Alzheimers Research and Treatment Center - Wellington
- Palm Beach Neurology and Premier Research Institute - West Palm Beach
California
- Irvine Clinical Research - Irvine
- Esperanza Clinical - Murrieta
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Arizona
- Xenoscience Inc. - Phoenix
Connecticut
- Yale University School Of Medicine - New Haven
Illinois
- Great Lakes Clinical Trials - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2032-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06544616
The ClinicalTrials.gov registry entry for NCT06544616 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 813-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (39% lower). The listed sponsor is Janssen Pharmaceutica N.V., Belgium, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preclinical Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06544616 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06544616 about?
NCT06544616 is a clinical study titled "A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease". The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
What is the current status of trial NCT06544616?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 498 participants. The study started on 2024-07-22. Estimated completion is 2032-07-16.
What conditions does trial NCT06544616 study?
This clinical trial studies the following conditions: Preclinical Alzheimer's Disease.
What interventions are being tested in trial NCT06544616?
The interventions under investigation include: Placebo (DRUG), JNJ-64042056 (DRUG).
Who is sponsoring clinical trial NCT06544616?
This trial is sponsored by Janssen Pharmaceutica N.V., Belgium, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544616 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preclinical Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alzheimer's Plasma Extension
ACTIVE NOT RECRUITING
-
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
ACTIVE NOT RECRUITING · Phase 3
-
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.